Q&A: Page 8

Exclusive interviews with industry leaders

  • Image attribution tooltip

    Permission granted by Mike Rea.

    Image attribution tooltip

    Innovation vs. invention

    IDEA Pharma’s indices ranks how well companies turn ideas into commercialized pharma products.

    Taren Grom • Feb. 9, 2022
  • headshot
    Image attribution tooltip
    Courtesy of Saniona
    Image attribution tooltip

    Saniona's CEO on why it takes a village to develop treatments for a rare disease

    Saniona built its village by first hiring a head of patient advocacy.

    Kim Ribbink • Feb. 8, 2022
  • diagram of man, doctor, phone, tablet
    Image attribution tooltip
    Retrieved from Google image.
    Image attribution tooltip

    Gaining real-world results from a decentralized trial

    Lark’s principal Investigator OraLee Branch hopes a DCT will lead the company to their true audience.

    Kelly Bilodeau • Feb. 8, 2022
  • Image attribution tooltip
    Courtesy of 23andMe
    Image attribution tooltip

    Why 23andMe's first solo clinical trial is a big deal

    It's the first test for a compound developed with the help of the company's genetic data — and there could be plenty more to come. 

    Taren Grom • Feb. 7, 2022
  • headshot
    Image attribution tooltip
    Permission granted by Mary Harmon
    Image attribution tooltip

    PTC's vice president of patient relations outlines the importance of patient input in rare disease R&D

    You can't know what matters to rare disease patients unless you ask them.

    Kim Ribbink • Feb. 3, 2022
  • headshot
    Image attribution tooltip
    Permission granted by Peter Anastasiou
    Image attribution tooltip

    New Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality

    Read what Capsida CEO Peter Anastasiou has planned for his new role. 

    Taren Grom • Feb. 3, 2022
  • Image attribution tooltip
    Retrieved from Rare Disease.org.
    Image attribution tooltip

    For the CEO of Travere, running a rare disease company is personal

    To kick off Rare Disease month, we interview the CEO of Travere Therapeutics

    Kim Ribbink • Feb. 1, 2022
  • Image attribution tooltip
    The image by Pixabay is licensed under CC BY 1.0
    Image attribution tooltip

    Foghorn's CEO on why collaborations are key to unlocking precision medicine

    With a major development deal under his belt, Adrian Gottschalk is helping the company advance its innovative platform.

    Robin Robinson • Jan. 28, 2022
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi's chief scientist on why 'this is the moment' for AI in Big Pharma

    How a $5.2 billion AI investment is enabling the French pharma to accelerate drug development. 

    Meagan Parrish • Jan. 27, 2022
  • Customers leave a Walgreens store that is set to be closed in the coming weeks on October 13, 2021 in San Francisco, California
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    With its wealth of patient data, Walgreens is looking to disrupt the clinical trial space

    How the mega-pharmacy’s clinical trials officer is looking to capitalize on its deep well of patient data to create an interconnected healthcare system of the future.

    Taren Grom • Jan. 26, 2022
  • photo of Ovid tweet
    Image attribution tooltip
    [photo]. Retrieved from Ovid Therapeutics.
    Image attribution tooltip

    Ovid's CEO shares his vision for rare disease developments

    Jeremy Levin, chairman and CEO of Ovid Therapeutics discusses the keys to success in rare disease innovation.

    Kim Ribbink • Jan. 10, 2022
  • Image attribution tooltip
    Justin Sullivan/ via Getty Images
    Image attribution tooltip

    How the executive VP of HR at Incyte is tackling pharma's hiring woes

    In an industry undergoing rapid growth, the increasing job opening rates and limited talent pool are taking on a new level of importance.

    Meagan Parrish • Jan. 10, 2022
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Last Word: PharmaVOICE The Next Frontier

    With Industry Dive acquiring PharmaVOICE, Taren Grom, Editor of PharmaVOICE, sat down with Davide Savenije, Editor-in-Chief of Industry Dive, to discuss what’s coming in 2022, and what you, our community, can expect with the relaunch in January. PV: After 20-plus years as a print publica...

    Davide Savenije • Nov. 15, 2021
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Last Word

    Six Keys to Beating the Odds and Achieving Startup Success Sharon Cunningham, Co-founder and CEO of Shorla Pharma, details the six steps she and her partner undertook to launch a successful biopharma company. PV: What was it like starting up Shorla Pharma? Cunningham: Starting your own c...

    Sharon Cunningham • Nov. 16, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Last Word

    The Impact Of COVID-19 On The Workplace Laurie Cooke, President and CEO of the Healthcare Businesswomen’s Association (HBA), highlights some of the ways the pandemic is impacting companies and employees across the industry. PV: The HBA conducted a survey among its corporate partner co...

    Laurie Cooke • Oct. 1, 2020
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Last Word

    Transforming the Practice of Medicine John Cox, CEO of Repertoire Immune Medicines — a clinical-stage immuno-therapy company — talks about unleashing the curative powers of the immune system to prevent and cure cancer, autoimmune, and infectious diseases. PV: Repertoire Therapeu...

    John Cox • April 1, 2020